GB202008961D0 - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- GB202008961D0 GB202008961D0 GBGB2008961.1A GB202008961A GB202008961D0 GB 202008961 D0 GB202008961 D0 GB 202008961D0 GB 202008961 A GB202008961 A GB 202008961A GB 202008961 D0 GB202008961 D0 GB 202008961D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (26)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2008961.1A GB202008961D0 (en) | 2020-06-12 | 2020-06-12 | Pharmaceutical composition |
| GB2019241.5A GB2596884B8 (en) | 2020-06-12 | 2020-12-07 | A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
| ES23157604T ES3007386T3 (en) | 2020-06-12 | 2021-06-14 | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
| EP21735380.4A EP3941904A1 (en) | 2020-06-12 | 2021-06-14 | Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine |
| AU2021289147A AU2021289147A1 (en) | 2020-06-12 | 2021-06-14 | Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
| CA3187020A CA3187020A1 (en) | 2020-06-12 | 2021-06-14 | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
| JP2022576811A JP2023530292A (en) | 2020-06-12 | 2021-06-14 | Compositions containing the benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
| CN202411802400.4A CN119613319A (en) | 2020-06-12 | 2021-06-14 | Compositions containing benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
| DK23157604.2T DK4279070T3 (en) | 2020-06-12 | 2021-06-14 | COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE |
| FIEP23157604.2T FI4279070T3 (en) | 2020-06-12 | 2021-06-14 | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
| CN202180055398.7A CN116056762B (en) | 2020-06-12 | 2021-06-14 | Compositions containing benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
| EP21735379.6A EP3941583B9 (en) | 2020-06-12 | 2021-06-14 | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
| KR1020237001336A KR20230024378A (en) | 2020-06-12 | 2021-06-14 | A composition comprising the benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
| EP24208163.6A EP4595962A3 (en) | 2020-06-12 | 2021-06-14 | Pharmaceutical composition |
| BR112022025306A BR112022025306A2 (en) | 2020-06-12 | 2021-06-14 | COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXIN, N-DIMETHYLTRIPTAMINE |
| EP23157604.2A EP4279070B1 (en) | 2020-06-12 | 2021-06-14 | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
| EP24213283.5A EP4483957A3 (en) | 2020-06-12 | 2021-06-14 | Pharmaceutical composition |
| PCT/GB2021/051476 WO2021250435A1 (en) | 2020-06-12 | 2021-06-14 | Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine |
| PCT/GB2021/051475 WO2021250434A1 (en) | 2020-06-12 | 2021-06-14 | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
| IL298871A IL298871A (en) | 2020-06-12 | 2021-06-14 | The composition consisting of the benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
| US17/660,981 US11518743B2 (en) | 2020-06-12 | 2022-04-27 | Pharmaceutical composition comprising 5-methoxy-N,N-dimethyltryptamine |
| US17/660,873 US11518742B2 (en) | 2020-06-12 | 2022-04-27 | Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
| US17/817,548 US11603353B2 (en) | 2020-06-12 | 2022-08-04 | Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
| US17/935,256 US11680044B2 (en) | 2020-06-12 | 2022-09-26 | Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine |
| US18/162,976 US20230348381A1 (en) | 2020-06-12 | 2023-02-01 | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
| US18/310,822 US20230382858A1 (en) | 2020-06-12 | 2023-05-02 | Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2008961.1A GB202008961D0 (en) | 2020-06-12 | 2020-06-12 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202008961D0 true GB202008961D0 (en) | 2020-07-29 |
Family
ID=71835429
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2008961.1A Ceased GB202008961D0 (en) | 2020-06-12 | 2020-06-12 | Pharmaceutical composition |
| GB2019241.5A Active GB2596884B8 (en) | 2020-06-12 | 2020-12-07 | A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2019241.5A Active GB2596884B8 (en) | 2020-06-12 | 2020-12-07 | A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
Country Status (1)
| Country | Link |
|---|---|
| GB (2) | GB202008961D0 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| PT3873883T (en) | 2019-11-07 | 2023-03-24 | Small Pharma Ltd | SYNTHESIS METHOD |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| EP4595962A3 (en) | 2020-06-12 | 2025-10-22 | Beckley Psytech Limited | Pharmaceutical composition |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2025068714A1 (en) * | 2023-09-28 | 2025-04-03 | Beckley Psytech Limited | Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1948155T3 (en) * | 2006-06-28 | 2012-10-31 | Chelsea Therapeutics Inc | Pharmaceutical compositions comprising droxidopa |
| WO2012173701A1 (en) * | 2011-06-16 | 2012-12-20 | President And Fellows Of Harvard College | Novel rodent control agents and uses thereof |
| WO2013063492A1 (en) * | 2011-10-28 | 2013-05-02 | Board Of Regents, The University Of Texas System | Novel compositions and methods for treating cancer |
-
2020
- 2020-06-12 GB GBGB2008961.1A patent/GB202008961D0/en not_active Ceased
- 2020-12-07 GB GB2019241.5A patent/GB2596884B8/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| GB2596884A (en) | 2022-01-12 |
| GB2596884B8 (en) | 2023-08-09 |
| GB2596884A8 (en) | 2023-08-09 |
| GB202019241D0 (en) | 2021-01-20 |
| GB2596884B (en) | 2022-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202019241D0 (en) | Pharmaceutical composition | |
| IL304290A (en) | Pharmaceutical composition | |
| GB201911517D0 (en) | Pharmaceutical composition | |
| IL300090A (en) | Pharmaceutical compositions comprising venglustat | |
| PL3908321T3 (en) | Pharmaceutical composition | |
| IL285728A (en) | Pharmaceutical composition | |
| GB202104224D0 (en) | Pharmaceutical composition | |
| GB202018068D0 (en) | Pharmaceutical composition | |
| GB202019335D0 (en) | Pharmaceutical compositions | |
| GB202208464D0 (en) | Pharmaceutical composition | |
| GB202109271D0 (en) | Pharmaceutical composition | |
| GB202108387D0 (en) | Pharmaceutical composition | |
| GB202107518D0 (en) | Pharmaceutical composition | |
| GB202105858D0 (en) | Pharmaceutical composition | |
| GB202105462D0 (en) | Pharmaceutical composition | |
| GB202105047D0 (en) | Pharmaceutical composition | |
| GB202105049D0 (en) | Pharmaceutical composition | |
| GB202102095D0 (en) | Pharmaceutical composition | |
| GB202102100D0 (en) | Pharmaceutical composition | |
| GB202101638D0 (en) | Pharmaceutical composition | |
| GB202101634D0 (en) | Pharmaceutical composition | |
| GB202101640D0 (en) | Pharmaceutical composition | |
| GB202101123D0 (en) | Pharmaceutical composition | |
| GB202100711D0 (en) | Pharmaceutical composition | |
| GB202020504D0 (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |